 Scynexis Inc NASDAQ: SCYX is taking out a loan to ensure it can hit the ground running for a potential commercial launch of ibrexafungerp for vaginal yeast infections as the PDUFA date of June 1 is just around the corner. The company closed terms on a 60 million loan with Hercules Capital and Silicon Valley Bank. 